Please assess the completion status of the following clinical trial:

Trial Title: Role of Methadone As Co-Opioid Analgesic

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Individual reporting average pain score for the last 24 hours that is at least a 4 on a numerical scale from 0 to 10 (0= no pain, 10=the worst possible pain) with a history of cancer (active or no evidence of disease).~2. Individual is receiving strong opioids (morphine, fentanyl, oxycodone, hydromorphone) for 3 weeks prior to enrollment.~3. Individual requires at least 150 mg of daily morphine equivalent daily dose for cancer pain. Using the formula MEDD = dose X MEDD Factor (App L) it would be follows: morphine: a 24 hour total oral intake (sum of PRN and around the clock doses) of 150 mg or greater would qualify the patient, for fentanyl alone: a 24 hour total transdermal intake of 75mcg/h or greater would qualify the patient, for oxycodone alone: a 24 hour total oral intake of 100 mg or greater would qualify the patient, and for hydromorphone alone: a 24 hour total oral intake of 30 mg/day or greater would qualify the patient.~4. Individual has the ability to receive morphine or methadone orally.~5. Individual has no known allergy of history of severe toxicity to morphine or methadone.~6. Individual has normal cognition defined as normal state of arousal and absence of obvious clinical findings of confusion, memory or concentration deficit.~7. Individual has adequate renal function (creatinine less or equal to 2.0 MG/DL)~8. Individual has a Zubrod performance status of 3 or lower.~9. Individual is willing to sign written informed consent.~10. Individual is 18 years of age or older.~11. Individual on stable doses(on same dose for at least one week) of nonopioid analgesics including NSAIDS, corticosteroids, gabapentin, pregabalin, or antidepressants prescribed for the purposes of pain control.~Exclusion Criteria:~1. Individual is determined incapable of completing the evaluation forms.~2. Individual with clinically evident impaired cognition.~3. Patient with MEDD greater than 600.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Morphine Only (Type: ACTIVE_COMPARATOR): Morphine - Arm 1: 2 Doses of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).Immediate-release morphine may be used, if needed, for pain.
- Morphine + Methadone (Type: ACTIVE_COMPARATOR): Arm 2: 1 Dose of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).).Immediate-release morphine may be used, if needed, for pain.~1 Dose of Methadone PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days)

Based on this trial design, predict the completion outcome and termination type (if applicable).